Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Cytosorbents (CTSO) EBT (2016 - 2025)

Cytosorbents (CTSO) has disclosed EBT for 14 consecutive years, with -$3.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBT fell 26.69% year-over-year to -$3.5 million, compared with a TTM value of -$13.6 million through Sep 2025, down 1180.12%, and an annual FY2024 reading of -$18.2 million, down 123.21% over the prior year.
  • EBT was -$3.5 million for Q3 2025 at Cytosorbents, up from -$4.2 million in the prior quarter.
  • Across five years, EBT topped out at $14.5 million in Q4 2023 and bottomed at -$12.2 million in Q3 2022.
  • Average EBT over 5 years is -$5.0 million, with a median of -$4.7 million recorded in 2021.
  • The sharpest move saw EBT crashed 662.9% in 2021, then skyrocketed 881.47% in 2023.
  • Year by year, EBT stood at -$10.0 million in 2021, then skyrocketed by 81.49% to -$1.9 million in 2022, then surged by 881.47% to $14.5 million in 2023, then plummeted by 129.97% to -$4.4 million in 2024, then increased by 19.44% to -$3.5 million in 2025.
  • Business Quant data shows EBT for CTSO at -$3.5 million in Q3 2025, -$4.2 million in Q2 2025, and -$1.5 million in Q1 2025.